









Markets
/
Stocks
/
nasdaq-pypd
/

PolyPid Ltd

PYPD

3.450USD

-0.050-1.43%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

54.01MMarket Cap

LossP/E TTM



PolyPid Ltd

3.450

-0.050-1.43%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

122 / 175

Overall Ranking

468 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

12.500

Target Price

+257.14%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Undervalued

The company’s latest PE is -0.92, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 7.60M shares, increasing 15.47% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Pharmaceuticals industry's average is 7.84.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -0.93, which is -66.58% below the recent high of -0.31 and 48.31% above the recent low of -0.48.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 122/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for PolyPid Ltd is 13.00, with a high of 14.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

12.500

Target Price

+257.14%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

PolyPid Ltd

PYPD

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 2.35, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 3.59 and the support level at 3.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.35

Change

-0.07

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(5)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.006

Neutral

RSI(14)

50.834

Neutral

STOCH(KDJ)(9,3,3)

52.686

Neutral

ATR(14)

0.121

Low Volatility

CCI(14)

57.309

Neutral

Williams %R

47.368

Neutral

TRIX(12,20)

-0.007

Sell

StochRSI(14)

62.346

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

3.428

Buy

MA10

3.446

Buy

MA20

3.433

Buy

MA50

3.474

Sell

MA100

3.299

Buy

MA200

3.103

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 74.58%, representing a quarter-over-quarter decrease of 0.78%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Aurum Ventures M.K.I.

2.03M

+0.56%

Centaurus Investments Limited

1.11M

+75.12%

Rosalind Advisors, Inc.

1.02M

Worth Venture Partners, LLC

429.43K

+55.80%

Nir (Yehuda)

613.91K

+11.36%

Hewlett Fund, L.P.

587.92K

+135.66%

Triple Gate Capital, LP

465.84K

AIGH Capital Management, LLC.

510.95K

-49.81%

Lukach (Aharon)

299.55K

-1.85%

Dafna Capital Management, LLC

291.27K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.87, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 1.51. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.